COST-EFFECTIVENESS ANALYSIS OF PANITUMUMAB PLUS MFOLFOX6 VERSUS BEVACIZUMAB PLUS MFOLFOX6 FOR FIRST-LINE TREATMENT OF PATIENTS WITH WILD-TYPE RAS METASTATIC COLORECTAL CANCER

被引：0
|
作者：
Graham, C. N. [1 ]
Hechmati, G. [2 ]
Hjelmgren, J. [2 ]
De Liege, F. [3 ]
Lanier, J. [3 ]
Knoof, A. [3 ]
Knox, H. [1 ]
Barber, B. [4 ]
de Pouvourville, G. [5 ]
机构：
[1] RTI Hlth Solut, Res Triangle Pk, NC USA
[2] Amgen Europe GmbH, Zug, Switzerland
[3] Amgen France SAS, Neuilly Sur Seine, France
[4] Amgen Inc, Thousand Oaks, CA 91320 USA
[5] ESSEC Business Sch, Cergy Pontoise, France
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.2264
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN106
引用
收藏
页码：A632 / A632
页数：1
相关论文
共 50 条
  • [41] Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma
    Rivera, Fernando
    Karthaus, Meinolf
    Hecht, J. Randolph
    Sevilla, Isabel
    Forget, Frederic
    Fasola, Gianpiero
    Canon, Jean-Luc
    Guan, Xuesong
    Demonty, Gaston
    Schwartzberg, Lee S.
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2017, 32 (08) : 1179 - 1190
  • [42] Efficacy and safety of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC).
    Zhou, Fuxiang
    Wang Wen-bo
    Xia, Ling
    Dai, Jing
    Wu, Han
    Yang, Lei
    Xiong, Zhiguo
    Gong, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 152 - 152
  • [43] CPGJ602 plus mFOLFOX6 as first-line treatment for patients with KRAS/NRAS/BRAF wild-type metastatic colorectal cancer: A randomized phase II study.
    Xu, Jianming
    Cao, Bangwei
    Gu, Kangsheng
    Bai, Yuxian
    Li, Wei
    Zhang, Jingdong
    Liu, Caigang
    Niu, Zuoxing
    Zhang, Liangming
    Zhong, Haijun
    Luo, Suxia
    Zhou, Jian-Wei
    Liu, Tianshu
    Gu, Yanhong
    Lin, Jingguan
    Deng, Yanhong
    Chen, Chuangqi
    Li, Yunfeng
    Yang, Xiuli
    Li, Bihui
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naive Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer
    Yoshino, Takayuki
    Uetake, Hiroyuki
    Tsuchihara, Katsuya
    Shitara, Kohei
    Yamazaki, Kentaro
    Oki, Eiji
    Sato, Takeo
    Naitoh, Takeshi
    Komatsu, Yoshito
    Kato, Takeshi
    Yamanaka, Kazunori
    Iwasaki, Kouji
    Soeda, Jumpei
    Hihara, Masamitsu
    Yamanaka, Takeharu
    Ochiai, Atsushi
    Muro, Kei
    CLINICAL COLORECTAL CANCER, 2017, 16 (02) : 158 - 163
  • [45] Cost-Effectiveness Analysis of Panitumumab Compared with Bevacizumab for First-Line Treatment of Patients with Wild-Type RAS Metastatic Colorectal Cancer in Germany
    Frank, M.
    Lange, A.
    Michailov, G.
    Lebioda, A.
    GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2016, 21 (04): : 203 - 209
  • [46] Phase 2 randomized controlled trial of intravenous or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 as first-line treatment of advanced gastric cancer
    Zhao, Shen
    Su, Liyu
    Chen, Yigui
    Li, Xiaofeng
    Lin, Peicheng
    Chen, Wujin
    Fang, Wenzheng
    Zhu, Jinfeng
    Li, Hui
    Ren, Liping
    Liu, Jie
    Hong, Yanni
    Lin, Shaowei
    Fan, Nanfeng
    Lin, Rongbo
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [47] First-line durvalumab plus monalizumab, mFOLFOX6, and bevacizumab or cetuximab for metastatic microsatellite-stable colorectal cancer (MSS-CRC)
    Wainberg, Zev A.
    Diamond, Jennifer Robinson
    Curigliano, Giuseppe
    Deva, Sanjeev
    Bendell, Johanna C.
    Han, Sae-Won
    Kalyan, Aparna
    Naidoo, Jarushka
    Kim, Richard D.
    Patel, Sandip Pravin
    Kourtesis, Panagiotis
    Li, Xia
    Ascierto, Maria
    Song, Xuyang
    Das, Mayukh
    Segal, Neil Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [48] Safety and efficacy of AMG 655 plus modified FOLFOX6 (mFOLFOX6) and bevacizumab (B) for the first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC)
    Saltz, L.
    Infante, J.
    Schwartzberg, L.
    Stephenson, J.
    Rocha-Lima, C.
    Galimi, F.
    Dillingham, K.
    Hsu, M.
    Wiezorek, J.
    Fuchs, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [49] Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) - Primary endpoint analysis of the CEBIFOX trial
    Kasper, S.
    Meiler, J.
    Knipp, H.
    Hoehler, T.
    Reimer, P.
    Steinmetz, T.
    Berger, W.
    Linden, G.
    Ting, S.
    Markus, P.
    Paul, A.
    Dechene, A.
    Kostbade, K.
    Schuler, M.
    Trarbach, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 99 - 100
  • [50] Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC): An interim analysis of the CEBIFOX trial.
    Kasper, Stefan
    Meiler, Johannes
    Knipp, Heike
    Hoehler, Thomas
    Reimer, Peter
    Steinmetz, Tilman
    Berger, Winfried
    Linden, Gabriele
    Ting, Saskia
    Markus, Peter
    Paul, Andreas
    Schuler, Martin H.
    Trarbach, Tanja
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345